Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Efficacy and Safety of Fexinidazole in Patients With Human African Trypanosomiasis (HAT) Due to Trypanosoma Brucei Rhodesiense: a Multicentre, Open-label Clinical Trial

NCT03974178 is registered in ClinicalTrials.gov with Drugs for Neglected Diseases as lead sponsor.

NCT NCT03974178
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03974178 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Efficacy and Safety of Fexinidazole in Patients With Human African Trypanosomiasis (HAT) Due to Trypanosoma Brucei Rhodesiense: a Multicentre, Open-label Clinical Trial
Lead sponsor
Drugs for Neglected Diseases
Phase
Phase 2/3
Overall status
Completed
Start date
September 29, 2019
Completion date
October 12, 2022
Enrollment
45 (actual)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

sleeping sickness, trypanosoma brucei rhodesiense; infection, trypanosomiasis, african